01—Abstract
Summary
Summary of the 10-K filed February 25, 2025. Cited figures are marked; the original filing is the authoritative source.
Merck & Co., Inc. (MRK) reported robust sales growth of 7% to $64.2 billiona in 2024, driven primarily by strong performance in oncology, cardiovascular, and animal health sectors.
The company's flagship oncology drug, Keytruda, saw a significant 18% increase in global sales, reaching $29.5 billionb and demonstrating continued strong demand across numerous indications and earlier-stage cancer treatments. The animal health segment also contributed positively with a 4% sales increase. Despite overall growth, the company experienced a decline in its diabetes franchise due to competitive pressures and Januvia/Janumet patent expirations, as well as reduced sales of Lagevrio (COVID-19 medication) and a notable dip in Gardasil/Gardasil 9 sales in China, a trend expected to continue into 2025.
Merck actively pursued strategic business development, including several key acquisitions and licensing agreements in the ophthalmology, immunotherapy, and oncology spaces, bolstering its pipeline. The company also advanced its regulatory submissions and secured numerous product approvals globally throughout 2024, highlighting its ongoing commitment to innovation and addressing unmet medical needs. Looking ahead, Merck faces potential headwinds from pricing pressures and government regulations, notably the Inflation Reduction Act (IRA), which is expected to impact Keytruda's U.S. sales in the future.
However, the company's diversified portfolio, strong pipeline, and strategic business development initiatives position it for continued growth. Investors should monitor developments in Keytruda's market exclusivity, the impact of the IRA on pricing, and the success of new product launches and pipeline advancements, particularly in oncology and cardiovascular diseases.
02—Key points
Key Highlights
- Total sales grew by 7% to $64.2 billion in 2024, with international sales up 1% (6% excluding foreign exchange).
- Keytruda sales increased by 18% to $29.5 billion, driven by demand across multiple indications and earlier-stage cancer treatments.
- Animal Health segment sales grew by 4% to $5.9 billion.
- Sales of Januvia/Janumet declined by 33% to $2.3 billion due to patent expirations and competitive pressures.
- Gardasil/Gardasil 9 sales decreased by 3% to $8.6 billion, primarily impacted by lower demand in China.
- The company actively engaged in business development with several acquisitions and licensing agreements to enhance its pipeline.
- Merck received over 25 regulatory approvals in major markets during 2024, including new indications for Keytruda and approvals for Winrevair and Capvaxive.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2024filed February 25, 2025Financial Statements
FY2024 against FY2023
| Line item | FY2024FY2023 | Change |
|---|---|---|
| Revenue | $64.17B$60.12B | +6.7% |
| Cost of Revenue | $15.19B$16.13B | −5.8% |
| Gross Profit | $48.98B$43.99B | +11.3% |
| R&D Expenses | $17.94B$30.53B | −41.2% |
| SG&A Expenses | $10.82B$10.50B | +3.0% |
| Net Income | $17.12B$365.00M | +4589.6% |
| EPS (Basic) | $6.76$0.14 | +4728.6% |
| EPS (Diluted) | $6.74$0.14 | +4714.3% |
| Shares Outstanding (Basic) | 2.53B2.54B | −0.2% |
| Shares Outstanding (Diluted) | 2.54B2.55B | −0.2% |
05—Questions
Frequently Asked Questions
What were Merck's key drivers of growth in 2024?
Merck's growth in 2024 was primarily driven by its oncology franchise, led by Keytruda, which saw strong demand across numerous indications. The cardiovascular franchise, particularly with the launch of Winrevair, and the Animal Health segment also contributed significantly to the company's sales growth.
What are the main challenges or concerns highlighted in the report?
Key challenges include ongoing pricing pressures globally, particularly from government regulations like the Inflation Reduction Act which is expected to impact future sales of certain products like Keytruda. Additionally, patent expirations for products such as Januvia/Janumet are leading to significant sales declines. The company also noted lower demand and inventory issues for Gardasil/Gardasil 9 in China, with expectations of continued sales declines in 2025.
How is Merck managing its product pipeline and future growth?
Merck is actively managing its pipeline through strategic business development, including several acquisitions and licensing agreements focused on oncology, ophthalmology, and immunotherapy. The company also continues to invest in its internal research and development, with numerous candidates in various stages of clinical development and regulatory review.
What is the outlook for Keytruda?
Keytruda continues to be a major growth driver, with sales increasing by 18% in 2024. The drug received numerous regulatory approvals for new indications globally. However, the company anticipates potential sales declines in the U.S. starting in 2028 due to the implementation of government price setting under the Inflation Reduction Act, and further declines upon market exclusivity loss following patent expiration in late 2028.
06—Continue